Relmada Therapeutics (RLMD) Misses Q1 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Trump: U.S. not seeking extension of Iran MOU
• Active options: AMD SNDK IREN GOOGL PLTR AVGO SOFI NKE MSTR NBIS ORCL